RenovoRx, Inc. (RNXT) Earnings Call Analysis
NASDAQ · Unknown · Unknown
Earnings Reports
-
RenovoRx (RNXT) Q1 2026: Active Cancer Centers Double to 16, Catalyzing Commercial Inflection
May 15, 2026
-
RenovoRx (RNXT) Q4 2025: Active Site Pipeline Triples, Anchoring $3-4M Revenue Target
March 31, 2026
-
RenovoRx (RNXT) Q3 2025: 24 Center Pipeline Signals Commercial Inflection Ahead of TIGER-PAC Data
November 13, 2025
-
RenovaRx (RNXT) Q2 2025: RenovoCath Sales Reach $422K as Phase 3 Trial Advances Without Data Bias
August 15, 2025